Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Xuzhou Medical University (Other)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

Condition or Disease Intervention/Treatment Phase
  • Drug: anti-siglec-6 CAR-T cell therapy
Phase 1/Phase 2

Detailed Description

Sialic acid-binding immunoglobulin-like lectins (Siglec) are a class of classical immunoglobulin-like lectins. Studies have shown that Siglec-6 is commonly expressed in AML but not detected on normal hematopoietic stem and progenitor cells (HSC/P). In vitro experiments revealed that anti-Siglec-6 CAR-T cell treatment did not affect the viability or lineage differentiation in colony-forming assays. These data suggest that anti-SigLlec-6 is an ideal target with great potential for treating acute myeloid leukemia.

Study Design

Study Type:
Anticipated Enrollment :
20 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Actual Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: anti-siglec-6 CAR-T cell therapy

anti-siglec-6 CAR-T cell therapy

Drug: anti-siglec-6 CAR-T cell therapy
Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Outcome Measures

Primary Outcome Measures

  1. Dose-limiting toxicity(DLT) [Baseline up to 28 days after T cell infusion]

    Adverse events assessed according to NCI-CTCAE v5.0 criteria

Secondary Outcome Measures

  1. MRD negative overall response rate (MRD- ORR) [3 months]

    Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment

  2. Overall response rate (ORR) [Month 6, 12, 18 and 24]

    Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24

  3. Event-free survival (EFS) [Month 6, 12, 18 and 24]

    Assessment of EFS at Month 6, 12, 18 and 24

  4. Overall survival (OS) [Time Frame: Month 6, 12, 18 and 24]

    Assessment of OS at Month 6, 12, 18 and 24

Eligibility Criteria


Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;

  2. At the age of 18-70 years old;

  3. Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);

  4. The patient has recovered from the toxicity of previous treatment;

  5. ECOG score ≤ 2 and expected survival period is not less than 3 months;

  6. Adequate organ function defined as:AST ≤3×ULN; ALT ≤3×ULN; Total bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN, or CCR≥60 mL/min; Hemoglobin ≥60g/L ; Indoor oxygen saturation ≥92%; LVEF≥45%;

  7. Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;

  8. From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception.

Exclusion Criteria:
  1. Diagnosis of acute promyelocytic leukemia;

  2. History or presence of a CNS disorder;

  3. HBsAg is positive; HCV 、HIV or Syphilis antibody are positive, CMV DNA in peripheral blood is more than≥500 copies /mL;

  4. History of severe hypersensitivity reaction;

  5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;

  6. History of organ transplant surgery;

  7. Required systemic application of immunosuppressive or other drugs;

  8. Auto-SCT within the 3 months before enrollment;

  9. Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));

  10. Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;

  11. Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;

  12. Live vaccine received within the ≤ 4 weeks before enrollment;

  13. Persons with serious mental illness;

  14. History of major surgical operations four weeks before enrollment;

  15. History of alcoholism or substance abuse;

  16. Was identified by the investigators as unsuitable to participate in the study.

Contacts and Locations


Site City State Country Postal Code
1 Kailin Xu Xuzhou Jiangsu China 221000

Sponsors and Collaborators

  • Xuzhou Medical University


  • Principal Investigator: Kailin Xu, M.D., Ph.D., The Affiliated Hospital of Xuzhou Medical University

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Kai Lin Xu,MD, President, Xuzhou Medical University Identifier:
Other Study ID Numbers:
  • XYFY2022-KL119-01
First Posted:
Aug 4, 2022
Last Update Posted:
Aug 4, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2022